Dashboard
Poor long term growth as Net Sales has grown by an annual rate of -4.77% and Operating profit at -27.59% over the last 5 years
The company has declared Negative results for the last 3 consecutive quarters
With ROE of 6.8, it has a Expensive valuation with a 0.9 Price to Book Value
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
INR 108 Cr (Micro Cap)
11.00
39
2.87%
-0.19
6.85%
0.76
Total Returns (Price + Dividend) 
Latest dividend: 3 per share ex-dividend date: Sep-19-2025
Risk Adjusted Returns v/s 
Returns Beta
News

Tyche Industries Stock Falls to 52-Week Low of Rs.114 Amidst Prolonged Downtrend
Tyche Industries, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.114, marking a significant milestone in its recent trading performance. The stock has been on a downward trajectory, reflecting a series of financial and market factors that have influenced investor sentiment and price movement.
Read More
Tyche Industries Stock Falls to 52-Week Low of Rs.116.85
Tyche Industries, a key player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.116.85, marking a significant price level for the stock amid a contrasting market environment.
Read More
Tyche Industries Falls to 52-Week Low of Rs.116.85 Amidst Sector Underperformance
Tyche Industries, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.116.85, marking a significant decline in its stock price amid broader market gains and sector challenges.
Read More Announcements 
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
13-Jan-2026 | Source : BSECompliance Certificate under Regulation 74(5) of SEBI (DP) Regulations2018 for the quarter ended December 31 2025
Closure of Trading Window
24-Dec-2025 | Source : BSEThe Trading window of the Company shall remain closed w.e.f January 1 2026 till the expiry of 48 hours after the declaration of Unaudited Financial Results of the Company for the 3rd quarter and Nine Months ended December 31 2025.
Announcement under Regulation 30 (LODR)-Newspaper Publication
15-Nov-2025 | Source : BSENewspaper publication of Financial Results for the 2nd quarter and half-year ended September 30 2025.
Corporate Actions 
No Upcoming Board Meetings
Tyche Industries Ltd has declared 30% dividend, ex-date: 19 Sep 25
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Silver Oak Technologies Private Limited (19.31%)
Plutus Techlabs Private Limited (6.4%)
26.51%
Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ
QoQ Growth in quarter ended Sep 2025 is 11.50% vs 2.67% in Jun 2025
QoQ Growth in quarter ended Sep 2025 is -37.45% vs 158.51% in Jun 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is -25.51% vs 8.98% in Sep 2024
Growth in half year ended Sep 2025 is -41.22% vs 14.87% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'24
YoY Growth in nine months ended Dec 2024 is -2.71% vs 10.40% in Dec 2023
YoY Growth in nine months ended Dec 2024 is 13.02% vs 0.70% in Dec 2023
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is -5.81% vs -7.80% in Mar 2024
YoY Growth in year ended Mar 2025 is 1.39% vs -13.62% in Mar 2024